Petosemtamab

Search documents
Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential
Yahoo Finance· 2025-10-02 20:55
Merus N.V. (NASDAQ:MRUS) ranks among the best biotech stocks to buy. On September 17, Barclays began coverage of Merus N.V. (NASDAQ:MRUS) with a price target of $112 and an Overweight rating. Barclays pointed out that the approval of zenocutuzumab for rare malignancies has commercially validated Merus’s platform. Source: Pixabay According to Barclays, Merus’s Phase 3 clinical asset, petosemtamab, is being investigated through two potentially registration-enabling Phase 3 trials for frontline and previou ...
80 亿美元!Genmab收购Merus
Xin Lang Cai Jing· 2025-09-30 04:32
此次要约收购中支付的每股普通股 97.00 美元的收购价格较 Merus 2025 年 9 月 26 日的收盘价 68.89 美 元溢价约 41%,较 Merus 30 天成交量加权平均价 67.42 美元溢价约 44%。 来源:市场资讯 (来源:求实药社) 当地时间 9 月 29 日,Genmab A/S 和 Merus NV 今日宣布,双方已达成交易协议。根据协议,Genmab 拟以每股 97.00 美元的价格全现金收购 Merus 的全部股份。此次收购将以现金方式进行,交易价值约为 80 亿美元。 该交易已获得两家公司董事会的一致批准。Genmab 的全资子公司将对 Merus 100% 的普通股发起要约 收购,预计将于 2026 年第一季度初完成。 | 0 = 00 | CARD STORE FOR CONSULTION CONSULTION CONSULTION OF CONSULTION OF | | --- | --- | | [ Global M Genmab | Nealthcare Professionals Patterco & Care Partnerships Contact AND ...
Genmab (NasdaqGS:GMAB) Earnings Call Presentation
2025-09-29 11:00
Acquisition Overview - Genmab is set to acquire Merus to deliver the next decade of sustainable growth[1, 5] - The offer price is $97 per share in cash, reflecting approximately $8 billion transaction value[24] - The tender offer for 100% of Merus' common shares is expected to close by early Q1 2026, subject to customary conditions[24] Strategic Rationale - The acquisition aligns with Genmab's 2030 Vision and capital allocation priorities[7] - It advances the shift to a wholly-owned model, positioning Genmab for sustainable long-term growth[7] - The deal is expected to be accretive to EBITDA by the end of 2029, with sustained revenue growth into the next decade[24] Petosemtamab Asset - Petosemtamab has two FDA Breakthrough Therapy Designations (BTDs) in 1L & 2L+ r/m HNSCC[7] - Topline readout of one or both 1L & 2/3L r/m HNSCC Phase 3 trials is expected in 2026[9, 15] - First launch is planned for 2027, with high confidence in multi-billion-dollar annual peak sales potential[7] Financial Impact - Genmab expects to fund the acquisition with a mix of cash on the balance sheet and $5500 million of new non-convertible debt[24] - The company anticipates returning to meaningful growth in 2027[24] - Genmab targets gross leverage of less than 30x within two years post-close[24]
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Avalo Therapeutics (NASDAQ:AVTX)
Benzinga· 2025-09-29 09:07
Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
GlobeNewswire News Room· 2025-05-22 21:30
Core Insights - Merus N.V. announced interim clinical data for petosemtamab in combination with pembrolizumab, showing a 63% response rate among evaluable patients and a 79% overall survival rate at 12 months [1][2][3] Clinical Data Summary - The ongoing phase 2 trial included 45 patients, with 43 evaluable for efficacy, showing a confirmed overall response rate of 63% (27/43) [3] - The median progression-free survival was reported at 9 months, with a median follow-up of 14.3 months [3] - Among the evaluable patients, 6 achieved complete responses and 21 had partial responses, with responses observed across different PD-L1 levels [3] - The combination treatment was generally well tolerated, with 60% of patients experiencing grade ≥3 treatment-emergent adverse events [3] Future Outlook - The company anticipates sharing top-line interim readouts from one or both phase 3 trials in 2026, indicating a strong belief in the potential of petosemtamab to become a new standard of care for head and neck cancer [2][3]
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Globenewswire· 2025-04-23 14:00
Core Insights - Merus N.V. announced the acceptance of an abstract for the presentation of interim clinical data on petosemtamab in combination with pembrolizumab for the treatment of PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) at the 2025 ASCO Annual Meeting [1][2] - The presentation will include data from a phase 2 trial involving 45 patients, showcasing early clinical efficacy and safety data [2][3] - The company believes petosemtamab has the potential to be a first and best-in-class treatment for r/m HNSCC, demonstrating substantial clinical activity superior to historical controls across multiple efficacy endpoints [3] Company Overview - Merus N.V. is focused on developing innovative full-length multispecific antibodies and antibody drug conjugates, referred to as Biclonics, Triclonics, and ADClonics [1][10] - Petosemtamab (MCLA-158) is a Biclonics low-fucose human full-length IgG1 antibody targeting EGFR and LGR5, designed to exhibit multiple mechanisms of action [6] - The company is conducting a phase 3 trial (LiGeR-HN1) to evaluate the safety and efficacy of petosemtamab in combination with pembrolizumab compared to pembrolizumab alone in r/m HNSCC patients [9] Industry Context - HNSCC is the sixth most common cancer globally, with over 930,000 new cases and more than 465,000 deaths reported in 2020 [8] - The incidence of HNSCC is expected to rise by 30%, surpassing 1 million new cases annually by 2030, indicating a growing need for effective treatment options [8]